Invacare Corp. cut some of its losses from a rough fiscal 2014, but the company's CEO has nonetheless decided to fire a key executive and take over leadership of the medical equipment manufacturer's North American businesses.
Intuitive Surgical, the manufacturer of the da Vinci surgical robot, reported a surge in earnings in the first quarter of 2015, thanks in large part to lower operating expenses.
Cardinal Health has agreed to pay $26.8 million as part of a settlement with the Federal Trade Commission that sparked disagreement among the commissioners about the agency's appropriate role.
Approval by the Food and Drug Administration of the new PCSK9 inhibitors would be an enormous boon to the drugmakers that developed them.
If left untreated, Stacey Lane's level of bad cholesterol would soar to more than four times what heart experts recommend. Help for her genetic disorder could come in the form of a new category of injectable drugs known as PCSK9 inhibitors, but it won't be cheap.
Robert Cascella has been tapped by Royal Philips to lead its imaging businesses. He replaces Gene Saragnese, who is expected to retire on May 1.
Xenex Disinfection Services, a maker of machines that use ultraviolet lights to kill germs in healthcare settings, is suing Clorox Co., which sells competing equipment and has taken issue with Xenex's marketing claims.
Variations in the way physicians use medical devices have a significant impact on determining patient outcomes and costs, a new study found.
Federal officials told lawmakers Tuesday that the 340B drug discount program needs greater transparency and more clarity about which providers and patients should be eligible.
Universal Hospital Services reported another 12 months of disappointing financial results with the healthcare technology and medical-device supplier recording a net loss of $66.5 million for the year ended Dec. 31, 2014.
The average cost of angiography systems dropped 25% in January compared with the same month last year, as buyers showed less interest in purchasing higher-end systems, according to the Modern Healthcare/ECRI Institute Technology Price Index.
New cost-effectiveness analyses of Sovaldi and other treatments to treat chronic hepatitis C infection suggest U.S. firms initially set prices near the ceiling that the United Kingdom's National Health Service will pay for drugs.